Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

In a corporate partnership many investors didn't see coming, chip maker Nvidia ( NVDA +1.59%) and pharmaceutical company Eli ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Pharmaceutical companies are paying thousands of Indiana doctors to talk about GLP-1 drugs, a WRTV Investigation has ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Jan 13 () - Global drugmakers are ramping up U. manufacturing and stockpiling inventory as the Trump administration considers ...

NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial ...

Novo Nordisk (NVO) downgraded to Hold after FDA GLP-1 actions and 2026 patent cliffs threaten Wegovy supply and growth. See ...

A worldwide leader in injectable drug administration will be the newest company to set up shop in Greenfield, and anticipates ...

The plant will focus on serving health care companies by developing and commercializing medical devices, drug delivery ...

Indiana Attorney General Todd Rokita has filed a lawsuit against Eli Lilly and Company, alleging that the drugmaker has ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...